Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 9
2011 7
2012 20
2013 28
2014 36
2015 45
2016 34
2017 35
2018 34
2019 32
2020 10
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

247 results
Results by year
Filters applied: . Clear all
Page 1
MLN8237 treatment in an orthoxenograft murine model for malignant peripheral nerve sheath tumors.
Payne R, Mrowczynski OD, Slagle-Webb B, Bourcier A, Mau C, Aregawi D, Madhankumar AB, Lee SY, Harbaugh K, Connor J, Rizk EB. Payne R, et al. J Neurosurg. 2018 Feb 1:1-11. doi: 10.3171/2017.8.JNS17765. Online ahead of print. J Neurosurg. 2018. PMID: 29473773
The MLN8237 group also showed decreased tumor size compared with the doxorubicin/ifosfamide group at the conclusion of the study (p = 0.036). ...A hazard ratio comparing the 2 treatment groups showed a decreased hazard rate in the MLN8237 group compared with the dox …
The MLN8237 group also showed decreased tumor size compared with the doxorubicin/ifosfamide group at the conclusion of the study (p = …
Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation.
Oku Y, Nishiya N, Sugiyama S, Sato H, Uehara Y. Oku Y, et al. Anticancer Res. 2018 Jun;38(6):3471-3476. doi: 10.21873/anticanres.12617. Anticancer Res. 2018. PMID: 29848699
RESULTS: Depletion of either YAP or TAZ sensitised these cell lines to MLN8237, resulting in apoptosis and reduction in aurora-A. MLN8237 reduced YAP/TAZ expression. A combination of MLN8237 with fluvastatin effectively reduced the cell viability of OVCAR-8 a …
RESULTS: Depletion of either YAP or TAZ sensitised these cell lines to MLN8237, resulting in apoptosis and reduction in aurora-A. …
MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D, Pettengell R. Alrifai D, et al. Expert Opin Investig Drugs. 2014 Dec;23(12):1731-6. doi: 10.1517/13543784.2014.972501. Epub 2014 Oct 17. Expert Opin Investig Drugs. 2014. PMID: 25323772 Review.
AREAS COVERED: The authors review the evidence for the orally administered aurora A kinase inhibitor MLN8237 ( alisertib ) in T-cell lymphoma. No significant association between clinical response and AAK expression has been observed but inhibition of this enzyme in a Phase …
AREAS COVERED: The authors review the evidence for the orally administered aurora A kinase inhibitor MLN8237 ( alisertib ) in T-cell …
c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
Li Y, Li X, Pu J, Yang Q, Guan H, Ji M, Shi B, Chen M, Hou P. Li Y, et al. Thyroid. 2018 Dec;28(12):1642-1654. doi: 10.1089/thy.2018.0183. Epub 2018 Oct 16. Thyroid. 2018. PMID: 30226440
However, the role of MLN8237 in thyroid cancer remains largely unclear. The aims of this study were to test the therapeutic potential of MLN8237 in thyroid cancer, and to analyze determinant factors affecting the response of thyroid cancer cells to MLN8237 an …
However, the role of MLN8237 in thyroid cancer remains largely unclear. The aims of this study were to test the therapeutic potential …
A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma.
Zhang K, Wang T, Zhou H, Feng B, Chen Y, Zhi Y, Wang R. Zhang K, et al. Mol Ther Nucleic Acids. 2018 Dec 7;13:176-188. doi: 10.1016/j.omtn.2018.08.014. Epub 2018 Sep 12. Mol Ther Nucleic Acids. 2018. PMID: 30292139 Free PMC article.
The activators of p-Akt and p-p38 MAPK signaling partially reversed the synergistic inhibitory effects of sorafenib and MLN8237 on HCC progression. Subsequent in vivo studies further confirmed the synergistic effects of sorafenib and MLN8237. Collectively, the newly …
The activators of p-Akt and p-p38 MAPK signaling partially reversed the synergistic inhibitory effects of sorafenib and MLN8237 on HC …
Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells.
Yang Y, Ding L, Zhou Q, Fen L, Cao Y, Sun J, Zhou X, Liu A. Yang Y, et al. Cancer Cell Int. 2020 Jan 7;20:9. doi: 10.1186/s12935-019-1072-y. eCollection 2020. Cancer Cell Int. 2020. PMID: 31920463 Free PMC article.
By contrast, MLN8237 treatment leads to abnormal high expression of AURKA in vitro and in vivo. ...Moreover, MLN8237 treatment followed by AURKA siRNA forces senescent cells into apoptosis via suppression of the Akt/Stat3 pathway. ...
By contrast, MLN8237 treatment leads to abnormal high expression of AURKA in vitro and in vivo. ...Moreover, MLN8237 treatment …
Domain-specific interactions between MLN8237 and human serum albumin estimated by STD and WaterLOGSY NMR, ITC, spectroscopic, and docking techniques.
Yang H, Liu J, Huang Y, Gao R, Tang B, Li S, He J, Li H. Yang H, et al. Sci Rep. 2017 Mar 30;7:45514. doi: 10.1038/srep45514. Sci Rep. 2017. PMID: 28358124 Free PMC article.
The present study provides a detailed characterization of the interaction of MLN8237 with a drug transport protein called human serum albumin (HSA). ...These competition experiments demonstrate that both spy molecules do not compete with MLN8237 for the specific bin …
The present study provides a detailed characterization of the interaction of MLN8237 with a drug transport protein called human serum …
Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.
Tayyar Y, Jubair L, Fallaha S, McMillan NAJ. Tayyar Y, et al. Crit Rev Oncol Hematol. 2017 Nov;119:59-65. doi: 10.1016/j.critrevonc.2017.09.006. Epub 2017 Sep 18. Crit Rev Oncol Hematol. 2017. PMID: 29065986 Review.
This resulted in the exploration of inhibitors of Aurora A kinase as a potential anti-cancer treatment. Alisertib (MLN8237) has proven to be a potent Aurora A kinase inhibitor that had the highest safety profile among its therapeutic family. ...
This resulted in the exploration of inhibitors of Aurora A kinase as a potential anti-cancer treatment. Alisertib (MLN8237) has prove …
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.
Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. Gay CM, et al. Oncologist. 2020 Oct;25(10):e1457-e1463. doi: 10.1634/theoncologist.2020-0610. Epub 2020 Jul 19. Oncologist. 2020. PMID: 32608142 Free PMC article.
Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of hepatoblastoma cells.
Eberherr C, Beck A, Vokuhl C, Becker K, Häberle B, Von Schweinitz D, Kappler R. Eberherr C, et al. Int J Oncol. 2019 May;54(5):1853-1863. doi: 10.3892/ijo.2019.4741. Epub 2019 Mar 5. Int J Oncol. 2019. PMID: 30864675
In addition, treating HB cells with the MYCN inhibitors JQ1 and MLN8237 led to the significant downregulation of MYCN either at the mRNA or protein levels, respectively. The underlying mechanism of action of the two inhibitors was revealed to be associated with the inducti …
In addition, treating HB cells with the MYCN inhibitors JQ1 and MLN8237 led to the significant downregulation of MYCN either at the m …
247 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page